( MENAFN - EIN Presswire) Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.
(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company's adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in the treatment of metastatic castration resistant prostate cancer (mCRPC). The data were presented today in an oral session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting by Aram Lyu, Ph.D.
, a postdoctoral fellow at Fred Hutch Cancer Center, University of California, San Francisco and Parker Scholar at the Parker Institute for Cancer Immunotherapy. Dr. Lyu's abstract, titled“Identification and therapeutic target of myeloid-mediated mechanisms of immunotherapy resistance in prostate cancer” was selected as a Top 100 abstract by SITC.
“These studies reveal important details on the role of the adenosine pathway on the immunobiology of mCRPC, including the importance of myeloid cells and the adenosine gene signature,” said Richard A. Miller, M.D.
, co-founder, president and chief executive officer of Corvus.“The mechanism is consistent with and builds on results from our clinical trials in renal cell cancer and prostate cancer, along with the potential for the adenosine gene si.
